and treat obesity (see box on page 2). Since 2003, the US Preventive Services Task Force (USPSTF) has noted the efficacy of screening for obesity in adults. In early 2010, the USPSTF added children aged 6 years and older to the patient population that should be screened for obesity and offered comprehensive, intensive behavioral interventions to promote improvement in weight status (grade B recommendation).
Physicians have long agreed that providing nutrition and obesity counseling to their patients was their responsibility; however, few of even motivated physicians do so. Physicians list a host of barriers including lack of time and training, inadequate reimbursement, and a dearth of evidence-based guidelines and resources. Physicians also state that they lack office support systems to provide continuous care to their patients.
Nevertheless, when it comes to pediatric obesity, practical guidelines and resources now exist to guide patient care. Moreover, Flocke and coworkers 3 have demonstrated that by taking busy physicians out of their day-to-day practice and asking them to reflect on ways to address healthy behaviors with patients, solutions to the perceived barriers can be identified.
In June 2007, recommendations for the assessment, prevention, and treatment of child and adolescent overweight and obesity were made by an expert panel from 15 health care agencies. The full report followed in a supplement to the journal Pediatrics in December 2007. 4 The recommendations outlined a staged treatment approach (4 Stages Model): Prevention Plus, Structured Weight Management, Comprehen sive Multidisciplinary Intervention, and Tertiary Care Intervention.
A variety of groups began designing toolkits to assist the primary care clinician in implementing the guidelines. Among them are The National Initiative for Children's Healthcare Quality (www.nichq.org), Eat Smart Move More North Carolina (www.eat smartmovemorenc.com/HealthCare. html), Massachusetts Blue Cross and Blue Shield Jump Up and Go (www.bluecrossma.com), and the California Medical Associa tion Foundation Obesity Prevention Project (www.calmedfoundation. org/projects/obesityProject.aspx).
The North Carolina tool kit was developed after a needs assessment of physicians and includes a clinician reference guide, colorcoded BMI charts, blood pressure charts, and prescription pads promoting prevention messages. All kits include as an essential step the calculation of the child's BMI percentile and counseling for the patient and family members. Researchers have documented that many factors affect the physician's ability to assess the size of a child and that visual inspection is insufficient. 5 Table 1 lists steps in the identification, evaluation, and treatment of overweight by using the 5As (assess, advise, agree, assist, and arrange) model of behavior change.
SCREEN FOR OBESITY: MEASURE BMI
In 2005, the USPSTF found adequate evidence that BMI was an acceptable measure for identifying children and adolescents with excess weight. It is practical, accurate, and sufficient for screening for obesity. Plotting BMI on a growth chart identifies the risk sooner than tracking stature for age or weight for age.
Clinicians have tended to overlook obesity during well child checks. The National Ambulatory Medical Care Survey for the period 1997-2000 found that obesity was diagnosed at 0.78% of all visits and at 0.93% of well child visits. At that time, it was estimated that 15% of children had greater than the 95th percentile BMI for age. In 2010, when an estimated 18% of 2-to 19-year-olds are above the 95th percentile, clinician adherence to obesity screening guidelines continues to be reported as suboptimal with only 46%, in one report, routinely calculating BMI. 5 5 For children younger than 2 years, the physician should follow growth, using weight for length. There is no single best way to incorporate this activity into office practice; each office must examine its flow and determine the most practi-cal way to measure and track BMI for children and find ways to assess.
AT RISK? OVERWEIGHT? OBESE? SEVERELY OR MORBIDLY OBESE?
There has been much debate about terminology. In the first set of pediatric obesity guidelines issued in 1998, 6 the term at risk for overweight was used for children falling between the 85th and the 94th percentile, with "overweight" being used for children at or above the 95th percentile. Some parents find the term obesity to be pejorative. Many professionals were either uncomfortable telling a child and parent that the child was "obese" or were concerned about stigmatization.
However, by 2007, many became concerned that the seriousness of the risks of excess body weight was not being acknowledged, and the expert committee recommended that the term obesity should replace overweight, and the term overweight should replace at risk of overweight. 4 In addition, cutoff points for the 99th percentile were given to denote "extreme obesity." The terms used with children and youth are not the same as the definitions for adult weight status.
COMMUNICATE THE DIAGNOSIS
Many clinicians choose to use the official diagnostic terms in the medical records, while using other terms when talking with children and parents so as to sensitively communicate this information. Parents often underestimate their children's weight and may be unaware of its consequences. One report 7 found that 60% of parents said that they knew what BMI meant but only a third could describe it accurately. Percentiles can be confusing since a high percentile is good in terms of academic scores. Parents may be skeptical that the BMI charts accurately reflect their child.
There is little in the literature to guide, so each physician needs to develop and practice delivering the message. The use of color-coded weight charts helps some clinicians communicate with the child and parents. The North Carolina charts use the familiar stop light color coding. "Red" is obese or underweight, "yellow" is overweight, and "green" is healthy weight. In one study, 85% of parents could describe the relationship of color coding to weight status. 7 
ASSESS READINESS TO CHANGE
Adult weight management guidelines specifically recommend assessing readiness to change. The assessment and treatment algorithms in most pediatric obesity toolkits include a step for assessing self-efficacy and readiness to change.
Woolford and colleagues 8 tested the feasibility and acceptability of a 1-page tool, The Assessment and Targeted Messages tool, in discussing obesity with parents of preschoolers. The tool included 2 questions on eating habits-"How ready are you to change your child's eating habits (scale of 1 not ready to 10 very ready)?" and "How confident are you that you can change your child's eating habits (same scale)?"-and similarly 2 questions on physical activity. About 62% of the physicians who participated in the study said that they would be somewhat likely to use the tool with only 23% indicating that they were very likely to do so.
GIVE HEALTHY LIFESTYLE MESSAGES
In the face of limited evidence that brief interventions are effective in the office setting, it is prudent to make recommendations to children and their families that: (1) might prevent obesity; (2) might promote other aspects of child health even if they do not impact obesity; and (3) are unlikely to cause harm. Several messages ( Table 2 ) are being used in the United Sates that have merit and evidence of benefit.
The Maine "Keep ME Healthy" program coined the "5-2-1-0" message: Eat fruits and vegetables at least 5 or more times on most days; Cut screen time to 2 hours or less daily; Participate in at least 1 hour or more of moderate physical activity every day and 20 minutes of vigorous activity at least 3 times a week; and restrict sodas and sugar-sweetened sports and fruit drinks.
The North Carolina clinicians were skeptical about the potential response from patients to a zero sugar-sweetened beverages message and, not finding evidence to support that approach, adopted a "5-3-2-1almost none" message. There is no evidence that one message is stronger than the others, and experts agree that locally recognized messages can be used.
REFER TO A REGISTERED DIETITIAN OR INTENSIVE PROGRAM
In treatment stages 2 and 3 outlined in the pediatric obesity guidelines, nutrition services might be provided by a registered dietitian.
Although the guidelines 4 do not outline the content of these visits, Henes and coworkers 9 describe a protocol that has an initial 60-minute session followed by six 30-to 45-minute follow-up sessions scheduled every 2 to 4 weeks. The KIDPOWER Protocol is available at www.ecu.edu/cs-dhs/ pedsweight center/mnt.cfm.
These authors suggest that the sessions be prioritized according to the typical food behaviors of the population being served. They report evidence that by the third visit, patients reported statistically significant changes in targeted behaviors in response to the counseling. A modest but significant improvement in weight status (BMI z score) was achieved. The targeted behaviors are similar to those advocated in the regional health promotion messages discussed earlier: limiting consumption of sugarsweetened beverages, eating at least 5 servings of fruits and vegetables each day, limiting meals eaten away from home, and limiting TV time. In the population Henes and colleagues 9 studied, almost 40% were consuming more than 20 ounces of soda, and Maine "Keep ME Healthy" 5-2-1-0 every day 5 or more fruits and vegetables 2 hours or less of recreational screen time 1 hour or more of physical activity 0 sugary drinks, more water, and low-fat milk www.letsgo.org
North Carolina "Eat Smart Move More" 5-3-2-1-almost none 5 or more servings of fruits and vegetables daily 3 structured meals daily-eat breakfast, less fast food, and more meals prepared at home 2 hours or less of TV or video games daily 1 hour or more of moderate to vigorous physical activity daily Limit sugar-sweetened drinks to "almost none" www.eatsmartmovemorenc. com
Women who give birth after bariatric surgery have a much lower rate of hypertensive complications than women who deliver before they undergo a weight loss procedure, a new study reports.
The relative risk of any hypertensive disorder during pregnancy was 75% lower among women who delivered after surgery compared with pregnancies in women who later had obesity surgery, according to Wendy L. Bennett, MD, MPH, of Johns Hopkins University, Baltimore, Maryland, and colleagues. 1 These women also had "substantially lower" rates of preeclampsia and eclampsia (odds ratio [OR], 0.20), chronic hypertension complicating pregnancy (OR, 0.39), and gestational hypertension (OR, 0.16).
The researchers searched insurance claims data for women who had undergone bariatric surgery and had at least 1 pregnancy and delivery between 2002 and 2006. Among the 585 women who met their criteria, there were 269 women who gave birth before surgery, and 316 women who delivered after the procedure. Gastric bypass accounted for 81.5% of the procedures performed.
65% were consuming more than 20 ounces of other sweet beverages (eg, sweet tea) a day at the time of the first visit.
It is helpful if the physician referring a patient to a dietitian reassures the patient that the dietitian is the team member who can provide the best food and nutrition education and it is important to keep the appointment. Reimbursement from third-party payers for these visits is improving. The 2010 USPSTF recommends referral for comprehensive weight management programs and describes the components of a moderate-to-intense program. 10 
BE AN ADVOCATE
The public supports the idea of physicians providing health-related expertise to local community organizations such as school boards and the local media. In one survey, obesity and nutrition were rated as very important issues for physician advocacy. 11 Bariatric Surgery and Pregnancy Outcomes Kevin Lomangino, Editor, Clinical Nutrition Insight
Learning Objective:
After participating in this activity, the clinician should be better able to describe the association between bariatric surgery and hypertensive complications in subsequent pregnancies.
KEY MESSAGES
o Bariatric surgery was associated with a 75% reduction in hypertensive complications of pregnancy in this retrospective analysis.
o Among other limitations, the study did not assess short-or long-term effects of bariatric surgery on the fetus.
Mr. Lomangino has disclosed that he has no significant relationships or financial interests in any commercial organizations pertaining to this educational activity.
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High doses of vitamins E and C do not prevent complications associated with hypertension in pregnancy, according to a large new randomized trial. 1 Researchers assigned 10,154 women who were giving birth for the first time to receive 1000 mg of vitamin C and 400 IU of vitamin E or placebo starting between the 9th and 16th weeks of pregnancy. They excluded women who had hypertension, proteinuria, or gestational diabetes.
The results show no differences between the groups in the primary outcome: severe pregnancy-associated hypertension alone or a composite of hypertension with other adverse outcomes such as elevated liver-enzyme levels, thrombocytopenia, elevated serum creatinine levels, eclamptic seizure, preterm birth, or perinatal death.
There was also no difference in preeclampsia rates between the groups and a nonsignificant increase in hypertension among women assigned to the supplement group. The results "effectively rule out vitamin C and E supplements as a means to prevent the hypertensive disorders during pregnancy, " said Alan Guttmacher, MD, of the National Institute of Child Health and Human Development, which funded the study, in a news release. 
Supplementation and Preeclampsia
Considering that maternal hypertension is associated with a wide range of adverse maternal and fetal outcomes, these results suggest that bariatric surgery "could be considered" in the preconception management of obese women who fit the criteria for weight loss surgery, Bennett et al. say. They add that the data "support insurance policies that cover and reduce barriers to bariatric surgery to improve pregnancy outcomes."
RETROSPECTIVE DATA
As with any retrospective analysis of observational data, this study is subject to error from selection bias and confounding. The researchers adjusted for numerous variables including maternal age at delivery, multiple pregnancy (twins or more), type of surgical procedure performed, preexisting diabetes, and insurance plan coverage. However, the BMI of the mother and the fetus's gestational age at delivery are also factors that conceivably could have affected the study's outcomes, according to Naomi Stotland, MD, of the University of California, San Francisco.
Stotland noted that preeclampsia becomes more prevalent with increasing gestational age. And she believes it is possible that women in 1 of the 2 groups could have been induced to deliver earlier than women in the other group. "It might be that women with a higher BMI are getting induced because the physician is worried about a big baby, or maybe the women who've had surgery are getting induced for whatever reason."
The point, said Stotland, is that earlier delivery might prevent some cases of hypertensive disorders, thereby influencing the study results. And so the study's methodology was, in her view, "pretty limited in terms of making broad generalizations about whether we should be recommending bariatric surgery to women."
That being said, Stotland noted that the findings were very consistent with the antihypertensive effects of bariatric surgery in nonpregnant individuals. And she said there were other studies pointing to benefits of surgery on subsequent perinatal complications.
LONG-TERM EFFECTS UNCLEAR
But a question that remains to be resolved is what effect the surgery might have on later outcomes in the children born to these women. Stotland said that nutrient deficiencies and other adverse effects of bariatric surgery might impact a critical period of "fetal programming" and increase the risk of diseases later in adulthood. Or it could be that bariatric surgery improves the nutritional environment in the womb and will lead to better health outcomes down the road.
"We just don't know the longterm effects on the baby, and we won't know those effects for a long time," Stotland said.
Dr. Stotland has disclosed that she has no significant relationships or financial interests in any commercial organizations pertaining to this educational activity. 1 whereas treatment with the anti glycemic agent pioglitazone failed to achieve a significant difference in the primary outcome compared with placebo. Pioglitazone did produce benefits on a number of secondary outcomes, researchers said, but its association with significant weight gain in the study "detracts from its long-term usefulness." Arun Sanyal, MD, of Virginia Commonwealth University in Richmond reported that 43% of partici-pants taking 800 IU of vitamin E (alpha-tocopherol) had improvement in a composite outcome of 4 histologic features of NASH, compared with 19% of placebo group participants. (The number needed to treat was 4.2.) Improvement was seen in 34% of participants taking 30 mg/d of pioglitazone (number needed to treat, 6.9), but this difference did not reach the threshold for statistical significance (P Ͻ .025) that was set by the investigators prior to the study. 1 Pioglitazone-treated patients did show significant improvement in individual components of liver disease including steatosis (fatty liver), inflammation, hepatocellular ballooning (swelling of hepatocytes indicating cell injury), and liver enzyme levels, in addition to an improvement in insulin resistance, the researchers pointed out. And more patients in the pioglitazone group actually had resolution of steatohepatitis compared with the vitamin E group (47% vs 36%). However, the pioglitazone-treated patients gained 4.7 kg during the study, and they did not lose the weight after discontinuing the drug.
UNEXPECTED FINDING
The vitamin E findings were "somewhat surprising," considering that some previous studies failed to show a significant effect from supplementation, said Zobair Younossi, MD, MPH, who is the vice president for Research for Inova Health System and also directs the Center for Liver Diseases at Inova Fairfax Hospital in Falls Church, Virginia. He said that the greater efficacy of vitamin E might be attributable to the fact that only nondiabetic patients with NASH were included in the trial.
"The one design issue I would point to is that the investigators recruited nondiabetic patients with NASH and then gave them an antidiabetic medication," he said in an interview. "You could have predicted that pioglitazone wouldn't be as impressive in this group because clinically overt type 2 diabetes did not seem to be an important factor contributing to their NASH. It seems that these patients had NASH where oxidative stress may have played a more important role in the pathogenesis of their liver disease, and that's probably
Learning Objective:
After participating in this activity, the clinician should be able to summarize clinical trial findings on vitamin E and pioglitazone for the treatment of nonalcoholic steatohepatitis.
KEY MESSAGES
o High-dose vitamin E, but not pioglitazone, significantly improved an endpoint of combined histologic features of nonalcoholic steatohepatitis (NASH) in this randomized controlled trial.
o Both agents improved a number of secondary outcomes including individual histologic features of NASH and liver enzymes.
o The pioglitazone group experienced significant weight gain.
Mr. Lomangino has also disclosed that neither vitamin E nor pioglitazone is approved by the FDA for treatment of liver disease.
Neither group of patients showed any decrease in fibrosis, which was characterized as the most important liver-related outcome for this population.
the reason why high-dose vitamin E reached significance."
Sanyal and colleagues randomized 247 adults with NASH and without diabetes to one of the 3 groups for 96 weeks-vitamin E, pioglitazone, or placebo. They performed liver biopsies in all patients at baseline and after treatment in 90% of patients. The primary outcome was improvement in histologic findings including improvement in the hepatocellular ballooning score, no increase in the fibrosis score, and a decrease in the nonalcoholic fatty liver disease score.
Overall, the findings indicate that "vitamin E was superior to placebo and suggested that pioglitazone may also have efficacy," according to Sanyal et al. 1 But they caution that the trial was not designed to compare vitamin E with pioglitazone, and therefore "no conclusions can be drawn about their relative efficacy." They added that although participants in the 2 treatment groups had no increase in adverse effects compared with placebo (apart from weight gain in the pioglitazone group), the trial was not powered to assess safetyrelated outcomes such as cardiovascular morbidity.
WHOM TO TREAT?
Younossi called the findings "encouraging," given that there are no currently proven treatments for NASH, but he cautioned that the benefits observed were "moderate." He noted that neither group of patients showed any decrease in fibrosis, which he characterized as the most important liver-related outcome for this population, and said that it would probably take several years of any treatment before benefit on this outcome could be ascertained.
Citing published studies that suggest that high-dose vitamin E might cause adverse effects in some patients, Younossi said that clinicians should be selective in choosing appropriate candidates for therapy. "The vast majority of patients who have only simple fat in their livers aren't going to progress to more advanced liver disease, and they don't need to be treated for their liver disease except to be reassured," Younossi said. He added that in his practice, he would approach each patient based on his or her biopsy findings as well as the associated metabolic conditions. It is very important to develop a "personalized" approach to treatment of patients with NASH, Younossi said.
Dr. Younossi has disclosed relationships with manufacturers of products to treat hepatitis C and hepatic encephalopathy, including Salix, Biolex, Vertex, Globimmune, and Tibotec.
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Of the 10% to 20% of Americans with nonalcoholic fatty liver disease, only about 2% to 5% have nonalcoholic steatohepatitis (NASH). NASH is characterized by fat in the liver in addition to clinical signs of inflammation and liver cell damage. 1 It is typically suspected when routine laboratory tests uncover elevations in liver enzymes and imaging studies confirm that there is fat in the liver.
To distinguish NASH from simple fatty liver, there must be additional biopsy evidence of inflammatory infiltrates and ballooning degeneration of hepatocytes. When clinical history shows convincingly that the patient consumes limited alcohol (Ͻ20 g/d) and other sources of liver disease (eg, viral hepatitis, medication) have been ruled out, NASH is diagnosed. Most patients with NASH remain stable over time with no worsening in their condition, while about 10% to 15% will progress to more advanced liver disease. What should nutrition professionals make of the claim that chemical pollutants are causing "grievous harm" to the American people and are a "grossly underestimated" cause of cancer?
These headline-grabbing statements were made recently by the President's Cancer Panel, 1 an advisory group of oncology experts whose 2 current members were appointed by George W. Bush. In its annual report, the panel warned that only about 200 of the roughly 80,000 chemicals on the market today have been thoroughly assessed by federal regulators for safety. "The American people-even before they are born-are bombarded continually with myriad combinations of these dangerous exposures, " said the panel.
The panel noted that children are especially vulnerable to chemical toxins, and suggested a number of steps consumers can take to limit their exposure to potential carcinogens. Precautionary measures include "choosing, to the extent possible, food grown without pesticides or chemical fertilizers and washing conventionally grown produce to remove residues" as well as "eating freerange meat" raised without antibiotics and growth hormones if it is available.
The panel's implicit endorsement of organics is one of many aspects of the report that have stirred controversy. Advocacy groups have embraced the report as an important milestone on the road to a cleaner environment, whereas industry representatives generally see it as a politically motivated sop to green activists. In this newsletter's view, the report is largely a positive development that will spur new investigation into promising areas of cancer research, but we agree that there are legitimate concerns about the sensational language used by the panel.
On the positive side, the report directs much-needed attention to the dearth of research on chemicals and lax government regulation of potential carcinogens. Importantly, it calls for a new "precautionary, prevention-oriented approach" to regulation that would replace our "current reactionary approaches in which human harm must be proven before action is taken to reduce or eliminate exposure. " The panel noted that current law places the burden of proof on the government to prove that a chemical is harmful (which usually happens only after the harm has already been done); a more rational framework would require manufacturers to show that a new chemical is safe before releasing it into the environment.
But critics are justified in objecting to the vocabulary the panel uses to communicate its message. The American Cancer Society, for example, complained that the panel presented "an unproven theory-that environmentally caused cases are grossly underestimated-as if it were a fact. " And it said the report "downplayed known risks that cause most cases of cancer including tobacco, obesity, alcohol, infections, hormones and sunlight. "
The American Cancer Society is correct to observe that there is no high-quality evidence to support the panel's more sweeping claims about the danger posed by environmental toxins. And by using over-the-top language to communicate risks that are still very much unclear (eg, "grievous harm, " "bombarded … with dangerous exposures"), the panel unfortunately steps over the fine line that separates good science from fear-mongering. As nutrition professionals are well aware, most Americans already have trouble achieving the recommended intake of health-promoting fruits and vegetables. This situation is unlikely to be improved by the panel's (as yet unsupported) suggestion that conventionally grown fruits and vegetables may cause cancer.
Tellingly, the most provocative statements from the panel were made in the cover letter to President Obama (the page most likely to be read by reporters and the media) and not in the body of the report itself. The conclusion from the report's executive summary gives a more balanced assessment of the current state of the science. It reads: "At this time, we do not know how much environmental exposures influence cancer risk and related immune and endocrine dysfunction. Environmental contamination varies greatly by type and magnitude across the nation, and the lifetime effects of exposure to combinations of chemicals and other agents are largely unstudied. Similarly, the cancer impact of exposures during key 'windows of vulnerability' such as the prenatal period, early life, and puberty are not well understood. "
The lack of strong proof of harm does not mean that prudent precautionary measures should not be taken to avoid exposure to chemicals that we know very little about. Nevertheless, in the face of considerable uncertainty about the risks, accurate, evidence-based statements are critical for consumers to make informed decisions about how to best protect their health. This and future issues of Clinical Nutrition Insight will be certified for CE credit only for registered dietitians, dietetic technicians, registered dietary managers, and certified home economists. Physicians can receive CME credit for the 2010 issues by visiting http://cme.lwwnewsletters.com.
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